Odanacatib

Odanacatib

File:Odanacatib Structural Formulae V.1.svg
Systematic (IUPAC) name
N-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide
Clinical data
Routes of administration	oral
Identifiers
CAS Number	603139-19-1 Y
ATC code	none
PubChem	CID: 10152654
IUPHAR/BPS	6478
ChemSpider	8328162 N
UNII	N673F6W2VH Y
ChEMBL	CHEMBL481611 N
Synonyms	(2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide
Chemical data
Formula	C25H27F4N3O3S
Molecular mass	525.56 g/mol
SMILES CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F
InChI InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1 N Key:FWIVDMJALNEADT-SFTDATJTSA-N N
NY (what is this?)  (verify)

Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.

It is being developed by Merck & Co.. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. Merck said it will apply for regulatory approval in 2015. Cowen and Co predicted it will bring a billion USD per year in sales by 2020.

This drug was developed at Merck Frosst in Montreal.